Abstract:Background: Schizophrenia is a devastating psychiatric disorder with a broad range of behavioural and biologic manifestations. There are several clinical characteristics of the illness that have been consistently associated with poor premorbid adjustment, long duration of psychosis prior to treatment and prominent negative symptoms. The etiopathogenic mechanisms of lack of insight in patients with schizophrenia are to date unknown, although several hypotheses have been suggested. A point of convergence for the theoretical models occurs with regard to the neuronal membrane. Neuronal membrane contains a high proportion of polyunsaturated fatty acid and is the site for oxidative stress. Oxidative stress is a state when there is unbalance between the generation of reactive oxygen species and antioxidant defence capacity of the body. It is closely associated with a number of diseases including Parkinson's disease, Alzheimer-type dementia and Huntington's chorea. Accumulating evidence points to many interrelated mechanisms that increase production of reactive oxygen or decrease antioxidant protection in schizophrenic patients. Objectives: This review aims to summarize the perturbations in antioxidant protection systems during schizophrenia, their interrelationships with the characteristic clinics and therapeutics and the implications of these observations in the pathophysiology of schizophrenia are discussed. Literature findings: In schizophrenia there is evidence for deregulation of free radical metabolism, as detected by abnormal activity of critical antioxidant enzymes (superoxide dismutase, glutathione peroxidase and catalase). Many studies conclude in the decrease in the activity of key antioxidant enzymes in schizophrenia. A few studies have examined levels of non enzymatic antioxidants such as plasma antioxidant proteins (albumin, bilirubine, uric acid) and trace elements. How showed decreased levels in schizophrenic patients. Others studies have provided evidence of oxidative membrane damage by examining levels of lipid peroxidation products. Such abnormalities have been associated with certain clinical symptoms and therapeutic features. Negative symptoms have been associated with low levels of GSH-Px. Positive symptoms have been positively correlated with SOD activity. Plasma TAS was significantly lower in drug-free and haloperidol treated patients with schizophrenia. A low erythrocyte SOD activity has been found in never-treated patients, but with haloperidol treatment, SOD activity increased. Discussion: These results demonstrate altered membrane dynamics and antioxidant enzyme activity in schizophrenia. Membrane dysfunction can be secondary to free a radical-mediated pathology, and may contribute to specific aspects of the schizophrenia symptomatology. Membrane defects can significantly alter a broad range of membrane functions and presumably modify behavior through multiple downstream biological effects. Phospholipid metabolism in the brain may be perturbed in schizophrenia, with reduced amounts of phosphatidylcholins and phosphatidylethanolamine in post-mortem brain tissue from schizophrenic patients, and large amounts of lipofuscin-like materiel in the oligodendrocytes. The existence of these products within cell membranes results in an unstable membrane structure, altered membrane fluidity and permeability and impaired signal transduction. Recent findings suggest that multiple neurotransmitter systems may be faulty. CNS cells are more vulnerable to the toxic effects of free radicals because they have a high rate of catecholamine oxidative metabolic activity. Neurotransmitters, like glutamate, can induce the same metabolic processes that increase free radical production and can lead to impaired dopamine-glutamate balance. These results question the role of this imbalance in the biochemical basis evoked in the etipathogenic mechanisms of schizophrenia, as well as the role of antioxidants in the therapeutic strategy and their implication in preventive and early intervention approaches in populations at risk for schizophrenia.

Serum Metabolomic Profiling Based on Fourier Transform-Ion Cyclotron Resonance-Mass Spectrometry: Do the Dysfunctions of Metabolic Pathways Reveal a Universal Risk of Oxidative Stress in Schizophrenia?

Serum Metabolomic Profiling Based on FT-ICR-MS: Do the Dysfunctions of Metabolic Pathways Reveal a Universal Risk of Oxidative Stress in Schizophrenia?

Imbalanced Free Radicals and Antioxidant Defense Systems in Schizophrenia: A Comparative Study

Serum Oxidative Stress Marker Levels in Unmedicated and Medicated Patients with Schizophrenia

Metabolomic Analysis Reveals Metabolic Disturbance in the Cortex and Hippocampus of Subchronic Mk-801 Treated Rats

Serum fatty acid patterns in patients with schizophrenia: a targeted metabonomics study

[Oxidative stress involvement in schizophrenia pathophysiology: a review]

Potential metabolite markers of schizophrenia

Caught in vicious circles: a perspective on dynamic feed-forward loops driving oxidative stress in schizophrenia

Metabolic profiling for water-soluble metabolites in patients with schizophrenia and healthy controls in a Chinese population: A case-control study.

A pilot study of biomarkers of oxidative stress in serum and schizophrenia

Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives

Serum metabolic profile evidence for relationship between schizophrenia and depression: An untargeted metabolomics

Plasma Metabolomics of Schizophrenia with Cognitive Impairment: A Pilot Study.

Metabolomic Profiling to Identify Potential Serum Biomarkers for Schizophrenia and Risperidone Action.

A Meta-Analysis of Oxidative Stress Markers in Schizophrenia

Salivary Metabolomics Reveals That Metabolic Alterations Precede the Onset of Schizophrenia

Schizophrenia Shows A Unique Metabolomics Signature in Plasma

Integrated Untargeted Fecal Metabolomics and Gut Microbiota Strategy for Screening Potential Biomarkers Associated with Schizophrenia

Lowered Antioxidant Defenses and Increased Oxidative Toxicity Are Hallmarks of Deficit Schizophrenia: Neurocognitive and Symptom Correlates

Lowered Antioxidant Defenses and Increased Oxidative Toxicity Are Hallmarks of Deficit Schizophrenia: a Nomothetic Network Psychiatry Approach